Medivir AB (MVR0) Price & Analysis

Q: What is Medivir AB’s market cap?

Medivir AB’s market cap is €105.07M.

Q: When is Medivir AB’s upcoming earnings report date?

Medivir AB’s upcoming earnings report date is Nov 05, 2026 which is in 55 days.

Q: How were Medivir AB’s earnings last quarter?

Medivir AB released its earnings results on Aug 20, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.003.

Q: Is Medivir AB overvalued?

According to Wall Street analysts Medivir AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Medivir AB pay dividends?

Medivir AB does not currently pay dividends.

Q: What is Medivir AB’s EPS estimate?

Medivir AB’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Medivir AB have?

Medivir AB has 624,037,050 shares outstanding.

Q: What happened to Medivir AB’s price movement after its last earnings report?

Medivir AB reported an EPS of -€0.003 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went up 2.727%.

Q: Which hedge fund is a major shareholder of Medivir AB?

Currently, no hedge funds are holding shares in DE:MVR0

0 Followers

MVR0 Stock Chart & Stats

€0.05

-€0.02(-6.27%)

At close: Jan 08 4:00 PM EST

€0.05

-€0.02(-6.27%)

Day’s Range― - ―

52-Week Range<€0.01 - €0.26

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€105.07M

Enterprise Value€754.42

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.60

Next Earnings

Nov 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding624,037,050

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.01

Revenue Forecast (FY)€452.96K

Medivir AB News

Medivir Bolsters Finances as Fostrox and MIV-711 Advance in Key Phase II Programs

Medivir AB ( ($SE:MVIR) ) just unveiled an announcement. Medivir reported first-half 2026 results showing modest net turnover...

23d ago

Medivir Expands Share Capital to Fund MIV-711 Orphan Indication

Medivir AB ( ($SE:MVIR) ) has issued an update. Medivir AB has completed an oversubscribed directed share issue...

1M ago

Medivir Shareholders Approve Directed Issue to Bolster Drug Development

Medivir AB ( ($SE:MVIR) ) has shared an update. Medivir AB, a Huddinge-based pharmaceutical developer listed on Nasdaq...

2M ago

Medivir secures long-term U.S. patent protection for fostrox–lenvatinib liver cancer combination

The latest announcement is out from Medivir AB ( ($SE:MVIR) ). Medivir AB has secured a Notice of...

2M ago

Medivir Expands Share Capital Following First Tranche of Directed Issue

Medivir AB ( ($SE:MVIR) ) just unveiled an update. Medivir AB has updated its share and vote count...

2M ago

Medivir Files Disclosure Document for Directed Share Issue on Nasdaq Stockholm

Medivir AB ( ($SE:MVIR) ) has issued an announcement. Medivir has prepared and published a disclosure document in...

3M ago

Medivir Calls Extraordinary General Meeting with Expanded Voting Options

Medivir AB ( ($SE:MVIR) ) has shared an announcement. Medivir AB has called an extraordinary general meeting for...

3M ago

Medivir Raises SEK 140 Million to Accelerate MIV‑711 Development in Rare Pediatric Disease

The latest announcement is out from Medivir AB ( ($SE:MVIR) ). Medivir has raised approximately SEK 140 million...

3M ago

Medivir Plans SEK 130 Million Directed Share Issue to Advance Rare Pediatric Disease Drug

Medivir AB ( ($SE:MVIR) ) has shared an update. Medivir plans to raise approximately SEK 130 million through...

3M ago

Medivir’s fostrox combo shows promising liver cancer data in key journal

Medivir AB ( ($SE:MVIR) ) has issued an update. Medivir AB reported that results from a phase 1b/2a...

3M ago

MVR0 FAQ

What was Medivir AB’s price range in the past 12 months?

Medivir AB lowest stock price was <€0.01 and its highest was €0.26 in the past 12 months.

What is Medivir AB’s market cap?

Medivir AB’s market cap is €105.07M.

When is Medivir AB’s upcoming earnings report date?

Medivir AB’s upcoming earnings report date is Nov 05, 2026 which is in 55 days.

How were Medivir AB’s earnings last quarter?

Medivir AB released its earnings results on Aug 20, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.003.

Is Medivir AB overvalued?

According to Wall Street analysts Medivir AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medivir AB pay dividends?

Medivir AB does not currently pay dividends.

What is Medivir AB’s EPS estimate?

Medivir AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medivir AB have?

Medivir AB has 624,037,050 shares outstanding.

What happened to Medivir AB’s price movement after its last earnings report?

Medivir AB reported an EPS of -€0.003 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went up 2.727%.

Which hedge fund is a major shareholder of Medivir AB?

Currently, no hedge funds are holding shares in DE:MVR0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatment of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711, a potent and selective cathepsin K inhibitor that is in a Phase II trial for the treatment of osteoarthritis, as well as in Phase I trials for the treatment of Osteogenesis Imperfecta (brittle bone disease) and Legg-Calvé-Perthes disease (LCPD); and fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication, which is in Phase I and II trials for the treatment of hepatocellular carcinoma. In addition, the company is developing birinapant, a SMAC-mimetic for the treatment of solid tumors; VBX-1000 (MIC-701), a selective cathepsin K inhibitor for the treatment of canine periodontitis; USP-7, a preclinical research program for the treatment of cancer; and MET-X (MBLI), a preclinical project for the treatment of infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.